Back

Systolic blood pressure variability and effect of finerenone treatment in patients with chronic kidney disease and type 2 diabetes: a FIDELITY analysis

29 August 2026 (08:35 - 08:45)
Organised by: Logo
Congress Presentation Part of: Secondary prevention after myocardial infarction Secondary Prevention ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Sanjay Rajagopalan

University Hospitals, Cleveland (United States of America)

5 More presentations in this session

Presentation thumbnail
The cardiovascular-kidney-liver-metabolic (CKLM) risk spectrum: synergistic mortality from liver fibrosis and cardiometabolic disease
Doctor S. Zuo (Xi'an, CN)
Abstract Slides Video
Presentation thumbnail
Impact of coronary computed tomography angiography image visualisation on low-density lipoprotein cholesterol reduction in non-obstructive coronary artery disease: a multicentre randomised trial
Doctor A. Kulasingam (Aarhus, DK)
Abstract Slides Video
Presentation thumbnail
Attainment of secondary prevention goals after myocardial infarction in foreign-born versus native-born patients: nationwide data from SWEDEHEART
Doctor S. Zwackman (Linkoping, SE)
Abstract Slides Video
Presentation thumbnail
Temporal trends and clinical predictors of GLP-1 receptor agonist and SGLT2 inhibitor use after myocardial infarction among patients with type 2 diabetes
Associate Professor G. Batra (Uppsala, SE)
Abstract Slides Video
Presentation thumbnail
Cross-physiological and fitness-adjusted assessment of rate–pressure product for residual mortality risk stratification in acute coronary syndrome
Mr H. Cui (Harbin, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Secondary prevention after myocardial infarction
Video

The Event

Event poster

ESC Congress 2026

29 August 2026 08:35 CET
You may be interested in
thumbnail
Congress Presentation
Effects of finerenone in patients with hypertensive nephropathy
30 August 2026
thumbnail
Congress Presentation
Effects of a novel low-dose triple combination on blood pressure variability: results from the TRIDENT trial
30 August 2026
thumbnail
Congress Session
Hypertension phenotypes and cardiovascular risk
31 August 2024
thumbnail
Congress Presentation
FIDELITY: Causes of mortality.
29 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources